 
Ophthalmology News Researchers Find New Way To Attack Inflammation In Graves' Eye Disease Sat, 07 Nov 2009 01:00:00 PST A small group of patients with severe Graves' eye disease experienced rapid improvement of their symptoms and improved vision following treatment with the drug rituximab. Inflammation around their eyes and damage to the optic nerve were significantly reduced. The same patients had not previously responded to steroids, a common treatment for Graves' eye disease. Raymond S. Douglas, M.D., Ph.D. Research Study Of Near Vision Fri, 06 Nov 2009 05:00:00 PST The Cornea and Laser Eye Institute is participating in a research study to determine if an investigational corneal inlay can safely and effectively reduce the need for reading glasses. Dr. Peter Hersh, the study doctor, will perform the procedures. The investigational AcuFocus Corneal Inlay (ACI) is intended to improve near vision in patients with presbyopia, which is the loss of near vision, and reduce dependency on reading glasses. What Is Graves' Disease? What Causes Graves' Disease? Fri, 06 Nov 2009 00:00:00 PST Graves' disease is an autoimmune disease in which the patient's own immune system attacks the thyroid gland, causing it to produce too much thyroxine. Thyroxine (T4) is a hormone produced by the thyroid gland that has four iodine molecules attached to its molecular structure. T4, as well as other thyroid hormones help regulate growth and control metabolism in the body. Graves' disease is a form of hyperthyroidism. Inspire Completes Patient Enrollment In Three Late-Stage Clinical Trials In Cystic Fibrosis, Dry Eye And Blepharitis Thu, 05 Nov 2009 20:00:00 PST Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today patient enrollment is complete in three of its late-stage clinical trials. "We are pleased to be executing on our strategic plan with the achievement of these patient enrollment milestones in the clinical development programs for denufosol, PROLACRIA™ and AZASITE®, as this places us in a position to have top-line results from all our late-stage clinical programs within 18 months. Testing Cutting-Edge Materials To Treat Eye Diseases Thu, 05 Nov 2009 00:00:00 PST Marking a significant bench to bedside research milestone in Singapore, the Institute of Bioengineering and Nanotechnology (IBN), the world's first bioengineering and nanotechnology research institute, and the National University Hospital (NUH) launched the IBN iCare and the NUH Eye Centre @ Biopolis at an official opening ceremony officiated by the Senior Minister of State for Trade and Industry and Education, S. Iswaran, at the Biopolis on Nov. 3, 2009.  |
